A Real-world Study of the Efficacy and Safety of Amlotinib for the Treatment of HER2-negative Advanced Breast Cancer

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and different molecular subtypes of breast cancer. Evidence-based medicine evidence for clinicians. Although the clinical application of amlotinib in breast cancer treatment is a supra-indication drug, in view of its high safety and possible good efficacy for advanced breast cancer, some patients have been clinically adopted to try the treatment after communicating with their families. This study provides evidence for the further use of amlotinib in breast cancer treatment by analysing the efficacy and safety of amlotinib in real-world applications.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Imaging or tissue/cell puncture, etc. confirmed recurrent, metastatic breast cancer

• Pathologically confirmed HER-2 negative

• Application of amlotinib treatment until disease progression or toxicity intolerable, or voluntarily give up the continuation of amlotinib treatment,amlotinib application for at least 2 cycles

• The clinical data are basically complete

Locations
Other Locations
China
The First Affiliated Hospital of Jilin University
RECRUITING
Changchun
Contact Information
Primary
Jiuwei Cui
jdyycjw@163.com
15843073215
Backup
Zheng Lv
lvz@jlu.edu.cn
15804301705
Time Frame
Start Date: 2024-02-04
Estimated Completion Date: 2025-06
Participants
Target number of participants: 153
Related Therapeutic Areas
Sponsors
Leads: The First Hospital of Jilin University

This content was sourced from clinicaltrials.gov